White matter

BioMed X Institute and Boehringer Ingelheim Successfully Complete Schizophrenia Research Project

Retrieved on: 
tisdag, maj 28, 2024
Wound healing, Partnership, Patient, Myelin, BioMed Central, DSM-IV codes, White matter, Reutlingen University, Boehringer Ingelheim, Psychiatry, Research, Pathology, Neuron, Gene, RNA, Fibrosis, Schizophrenia, Bipolar disorder, PMID, Cell Press, EPD, Medical imaging

HEIDELBERG, Germany, May 28, 2024 - (ACN Newswire) - German independent research institute BioMed X announces the successful completion of its second neuroscience project in partnership with Boehringer Ingelheim in the field of psychiatric disorders.

Key Points: 
  • HEIDELBERG, Germany, May 28, 2024 - (ACN Newswire) - German independent research institute BioMed X announces the successful completion of its second neuroscience project in partnership with Boehringer Ingelheim in the field of psychiatric disorders.
  • The data resulting from this project have been acquired by Boehringer Ingelheim, where this research will be continued, potentially paving the way for novel therapies.
  • This research project was launched in 2020 at the BioMed X Institute in Heidelberg and led by Dr. Ebru Ercan Herbst, now a professor at Reutlingen University, Germany.
  • Dr. Christian Tidona, Managing Director & Founder of the BioMed X Institute: "This is already our second successfully completed project with Boehringer Ingelheim in the field of psychiatry.

Artificial Intelligence Tool Detects Sex-Related Differences in Brain Structure

Retrieved on: 
tisdag, maj 14, 2024
NYU Langone Health, Bangladesh Technical Education Board, Doctor of Philosophy, Migraine, Machine learning, Scientific Reports, MRI, Male, Radiology, White matter, Multiple sclerosis, AI, Magnetic resonance imaging, Research, Artificial intelligence, Eye, NYU, Psychiatry, DSM-IV codes, Woman, Communication, Brain, Spectrum, Water, Female, Medical imaging

NEW YORK, May 14, 2024 /PRNewswire/ -- Artificial intelligence (AI) computer programs that process MRI results show differences in how the brains of men and women are organized at a cellular level, a new study shows. These variations were spotted in white matter, tissue primarily located in the human brain's innermost layer, which fosters communication between regions.

Key Points: 
  • Men and women are known to experience multiple sclerosis, autism spectrum disorder, migraines, and other brain issues at different rates and with varying symptoms.
  • A detailed understanding of how biological sex impacts the brain is therefore viewed as a way to improve diagnostic tools and treatments.
  • However, while brain size, shape, and weight have been explored, researchers have only a partial picture of the brain's layout at the cellular level.
  • According to the authors, the team next plans to explore the development of sex-related brain structure differences over time to better understand environmental, hormonal, and social factors that could play a role in these changes.

Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024

Retrieved on: 
torsdag, maj 9, 2024
Disorder, Common, Risk, GC, Overweight, Trial of the century, Adrenocorticotropic hormone, Hyperlipidemia, Associate, Deficit spending, Hydrocortisone, Neurocrine Biosciences, White matter, Food, Oklahoma State University–Stillwater, Cognition, Psychology, Testosterone, Male, Literature, Brain, DSM-IV codes, A4, SAN, GCS, CAH, Acne, Safety, Glucocorticoid, Research, Depression, Congenital adrenal hyperplasia, Osteopenia, Anxiety, Division, Hirsutism, Androstenedione, Psychiatry, Psychosis, Hypertension, Metabolism, Poster, Pharmaceutical industry

The CAHtalyst Adult study baseline data demonstrate the potential long-term consequences of current CAH treatments, with many patients in young adulthood experiencing disorders found more commonly in people decades older, including osteopenia, hypertension and hyperlipidemia.

Key Points: 
  • The CAHtalyst Adult study baseline data demonstrate the potential long-term consequences of current CAH treatments, with many patients in young adulthood experiencing disorders found more commonly in people decades older, including osteopenia, hypertension and hyperlipidemia.
  • These new data were presented at oral presentations and poster sessions at the American Association of Clinical Endocrinology 2024 Annual Meeting in New Orleans.
  • Despite supraphysiologic GC dosing, levels of adrenocorticotropic hormone, 17-hydroxyprogesterone and androstenedione (A4) were elevated at baseline, with levels of testosterone (females) and A4/testosterone (males) also elevated.
  • The data from both studies supported two New Drug Applications submitted to the U.S. Food and Drug Administration in April 2024.

BrainTale Accelerates Its International Expansion and Unveils Tier-one Collaborations to Improve Brain Care and Enable Precision Neurology

Retrieved on: 
måndag, maj 6, 2024
Technology, Neurology, Professional Services, Software, Biotechnology, Radiology, Health, Data Analytics, Artificial Intelligence, DSM-IV codes, DTI, Brain, University, Hospital, Injury, Diffusion, Stroke, White matter, Safety, AI, Leukodystrophy, Doctor of Philosophy, Research, Patient, Master of Science, Brain damage, MRI, Caregiver, Harvard Medical School, Multiple sclerosis, Mass General Brigham, Drug development, Ageing, Biomarker, Associate, Myenteric plexus, Nursing care plan, Pharmaceutical industry

BrainTale, a medtech deciphering white matter to enable better brain care, spin-off of the Paris Region Greater Hospitals, unveils today a selection of leading research centers collaborations.

Key Points: 
  • BrainTale, a medtech deciphering white matter to enable better brain care, spin-off of the Paris Region Greater Hospitals, unveils today a selection of leading research centers collaborations.
  • Accordingly, since its creation in 2018, BrainTale has been developing non-invasive, accessible, actionable and clinically validated measurement and predictive tools for patients suffering from brain diseases.
  • With a strong collaborative approach, the company’s ambition is to provide investigators with relevant measure of the brain to improve patient care and clinical development of new disease-modifying drugs.
  • « Our collaborative approach is the foundation of BrainTale’ strategy to establish white matter measure as a reference to ultimately contribute to a better brain care.

Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab

Retrieved on: 
torsdag, april 25, 2024
American Academy, Brain, White matter, Mass, Expanded access, Hospital, Encephalitis, PET, Research, EDSS, Patient, MFIS, Fatigue, DSM-IV codes, Harvard Medical School, Associate, Disability, PIRA, Medical imaging

White Matter Z-scores are a statistical measure used in neuroimaging studies to assess the integrity or abnormalities in structures of the brain.

Key Points: 
  • White Matter Z-scores are a statistical measure used in neuroimaging studies to assess the integrity or abnormalities in structures of the brain.
  • We calculated White Matter Z-scores to measure the effect of intranasal foralumab on microglial activation at baseline and then after foralumab treatment for three months.
  • I welcome the publication of Dr. Singhal’s [F18]PBR06-PET research paper, highlighting these combined findings in Clinical Nuclear Medicine,” commented Gabriele Cerrone, Chairman, acting CEO and founder of Tiziana Life Sciences.
  • *EA5 showed a worsening in their White Matter Z-Score at three months during a pseudo-exacerbation of the patient’s trigeminal neuralgia.

Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology

Retrieved on: 
torsdag, april 18, 2024
American Academy, Mass, Hospital, Stabilizer, White matter, PET, EDSS, Human, Patient, MFIS, Fatigue, DSM-IV codes, Harvard Medical School, Biomarker, Annual general meeting, Associate, Microsoft Access, Neuro, PIRA, Medical imaging

The presentation includes new, encouraging quantitative imaging data from foralumab’s intermediate- size patient population Expanded Access Program.

Key Points: 
  • The presentation includes new, encouraging quantitative imaging data from foralumab’s intermediate- size patient population Expanded Access Program.
  • Gabriele Cerrone, Chairman, acting CEO and founder of Tiziana Life Sciences, commented, “Tiziana is taking a leadership role in focusing on this subset of progressive MS where there are no effective treatments.
  • The study is designed to be open-label and part of the Expanded-Access Program evaluating foralumab in na-SPMS patients that is currently underway.
  • This trial ( NCT06292923 ) is important because if the potential to slow disease progression is demonstrated this would align with early treatment intervention.

NYU Langone Neurologists Present Latest Clinical Findings & Research at AAN 2024

Retrieved on: 
lördag, april 13, 2024
Neuroimaging, American Academy, Brain, MCI, Stroke, White matter, Risk, Professor, News, NYU Langone Health, Doctor of Philosophy, Research, Appreciation, NYU, Deficit spending, Patient, AAN, Neurosurgery, Headache, Prevalence, MRI, Job satisfaction, Faculty, DSM-IV codes, Philip, Traumatic brain injury, Migraine, Practice, Biomarker, Annual general meeting, Organization, Growth, Medical imaging

DENVER, April 13, 2024 /PRNewswire/ -- Experts from NYU Langone's Department of Neurology present their latest clinical findings and research discoveries at the American Academy of Neurology (AAN) 2024 Annual Meeting, April 13 to 18, in Denver.

Key Points: 
  • DENVER, April 13, 2024 /PRNewswire/ -- Experts from NYU Langone's Department of Neurology present their latest clinical findings and research discoveries at the American Academy of Neurology (AAN) 2024 Annual Meeting, April 13 to 18, in Denver.
  • U.S. News & World Report's "Best Hospitals" ranks NYU Langone the No.
  • Researchers at NYU Langone surveyed 90 clinicians, residents, and fellows to identify the best methods of showing neurologists that they are valued in order to improve their job satisfaction and reduce burnout.
  • Further research is warranted to validate these findings and their potential to enhance early detection and intervention strategies for Alzheimer's disease.

MINDSET Integrated Co. And US Radiology Specialists, Inc. Announce Strategic Agreement On Brain Injury Assessment

Retrieved on: 
tisdag, mars 19, 2024
MRI, White matter, DTI, Quantify, Patient, Brain, TBI, Radiology, Motion, Doctor of Philosophy, Magnetic resonance imaging, Google Images, Traumatic brain injury, Medical imaging

ALBUQUERQUE, N.M. and RALEIGH, N.C., March 19, 2024 /PRNewswire-PRWeb/ -- US Radiology Specialists Inc. (US Radiology) and MINDSET Integrated Co. (MINDSET®) today announced an expanded strategic distribution agreement. This collaboration will significantly increase access to MINDSET's quantitative volumetric magnetic resonance imaging (MRI) and diffusion tensor imaging (DTI) analysis software, Quantify®, across the US Radiology network.

Key Points: 
  • Cutting-edge quantitative volumetric and DTI analysis solution for brain injury expands to the US Radiology network of over 180 patient imaging sites.
  • ALBUQUERQUE, N.M. and RALEIGH, N.C., March 19, 2024 /PRNewswire-PRWeb/ -- US Radiology Specialists Inc. (US Radiology) and MINDSET Integrated Co. (MINDSET®) today announced an expanded strategic distribution agreement.
  • "We believe MINDSET's Quantify reporting allows us to provide the most comprehensive clinical information pertaining to traumatic brain injury.
  • Additionally, more sites across US Radiology are scheduled to come online in the coming months, further expanding the company's reach and capabilities.

Philips teams with SyntheticMR to deliver breakthrough AI-based quantitative brain imaging in MR to advance neurology care for patients

Retrieved on: 
fredag, mars 1, 2024
MRI, Acquisition, CE, White matter, Myenteric plexus, 2D, AI, Traumatic brain injury, Magnetic resonance imaging, FDA, Synthetic, Cerebrospinal fluid, 3D, Neurodegenerative disease, TBI, Radiology, Multiple sclerosis, DSM-IV codes, PHG, Quant, Health, Patient, Dementia, Diagnosis, Software, AEX, Brain, Medical imaging

As healthcare providers strive to deliver high-quality care to patients, at #ECR2024 Philips is partnering with its customers to improve productivity and access to more sustainable healthcare.

Key Points: 
  • As healthcare providers strive to deliver high-quality care to patients, at #ECR2024 Philips is partnering with its customers to improve productivity and access to more sustainable healthcare.
  • Philips' exclusive agreement with SyntheticMR makes it the only company currently able to offer SyMRI NEURO 3D capability on MR scanners.
  • Accurate measurement of the volume and distribution of different tissue types in the brain is important for diagnosing brain disease.
  • "Smart Quant allows for shorter exams and exploration of quantitative metrics, which show great potential to better stratify patients with similar imaging characteristics on conventional MR sequences.

INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024

Retrieved on: 
tisdag, februari 6, 2024
TNF, Science, Axon, MD, MCI, Neurology, CFS, Acquisition, White matter, University of Florida, Doctor of Philosophy, University, Webcast, NFL, Pharmaceutical industry

Boca Raton, Florida, Feb. 06, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer’s disease (AD) with XProTM (XPro1595; pegipanermin), a dominant-negative inhibitor of soluble TNF, announces its management will be participating in Baird’s Biotech Discovery Series webcast on Tuesday, February 13, 2024 at 10:30AM EST.

Key Points: 
  • Boca Raton, Florida, Feb. 06, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer’s disease (AD) with XProTM (XPro1595; pegipanermin), a dominant-negative inhibitor of soluble TNF, announces its management will be participating in Baird’s Biotech Discovery Series webcast on Tuesday, February 13, 2024 at 10:30AM EST.
  • The speakers will cover two key topics – first, they will provide an update on the unique features of the Company’s  ongoing blinded, randomized, placebo-controlled Phase II trial for Early Alzheimer's disease (MCI/Mild AD).
  • Baird’s Biotech Discovery Series, which launched in early 2022, is an opportunity for investors to hear directly from interesting and innovative public and private biotech companies in a fireside chat format.
  • We invite key members of management and frequently ask related third parties to join the discussion to learn why they are excited about the science and opportunity for these emerging biotech leaders.